Consort Medical signs multi–year supply agreement for drug dose
5 February 2015
Hemel Hempstead-based Consort Medical plc has announced the
conclusion of a new commercial supply agreement for its proprietary
integrated dose counter (IDC) system.
The multi-year supply agreement covers supply of both the IDC
actuator and the pressurised metered dose inhaler (pMDI) valve. This
IDC programme represents the first commercial oral variant of the
device, which is already approved and marketed for a nasally
Dose-counting devices fulfil an important patient and compliance
need to let patients know if their device contains sufficient drug
and to indicate when they need to seek a further prescription. It
provides patients with a reliable, easy to read indication of how
many doses are left inside the canister in line with FDA guidance.
Jonathan Glenn, Consort Medical’s Chief Executive Officer
“Consort Medical has a long heritage of excellence,
reliability and innovation and we strive to be the partner of choice
for pharmaceutical companies, enabling them to implement drug
delivery technologies that can streamline and accelerate the route
to market for their drugs.
“With the conclusion of this agreement for our IDC device we have
reinforced the ongoing strength of our respiratory device franchise,
in particular in the pMDI segment, and created a significant
The device will be manufactured in the Consort Medical company
Bespak’s existing IDC facility at King’s Lynn. The project will be
referred to as (IDC300).
Source: Consort Medical